492 related articles for article (PubMed ID: 35805939)
1. Novel Drugs with High Efficacy against Tumor Angiogenesis.
Qi S; Deng S; Lian Z; Yu K
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805939
[TBL] [Abstract][Full Text] [Related]
2. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
3. Angiopoietin inhibitors: A review on targeting tumor angiogenesis.
Parmar D; Apte M
Eur J Pharmacol; 2021 May; 899():174021. PubMed ID: 33741382
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of angiopoietins in tumor angiogenesis and cancer development.
Thapa K; Khan H; Kaur G; Kumar P; Singh TG
Biochem Biophys Res Commun; 2023 Dec; 687():149130. PubMed ID: 37944468
[TBL] [Abstract][Full Text] [Related]
5. AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo.
Zhang PC; Liu X; Li MM; Ma YY; Sun HT; Tian XY; Wang Y; Liu M; Fu LS; Wang YF; Chen HY; Liu Z
Biochem Pharmacol; 2020 Feb; 172():113771. PubMed ID: 31863779
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.
Nagaraju GP; Park W; Wen J; Mahaseth H; Landry J; Farris AB; Willingham F; Sullivan PS; Proia DA; El-Hariry I; Taliaferro-Smith L; Diaz R; El-Rayes BF
Angiogenesis; 2013 Oct; 16(4):903-17. PubMed ID: 23838996
[TBL] [Abstract][Full Text] [Related]
7. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer.
Nagaraju GP; Zhu S; Ko JE; Ashritha N; Kandimalla R; Snyder JP; Shoji M; El-Rayes BF
Cancer Lett; 2015 Feb; 357(2):557-65. PubMed ID: 25497868
[TBL] [Abstract][Full Text] [Related]
9. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.
Sanderson S; Valenti M; Gowan S; Patterson L; Ahmad Z; Workman P; Eccles SA
Mol Cancer Ther; 2006 Mar; 5(3):522-32. PubMed ID: 16546966
[TBL] [Abstract][Full Text] [Related]
10. Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer.
Shanmugam MK; Warrier S; Kumar AP; Sethi G; Arfuso F
Curr Vasc Pharmacol; 2017; 15(6):503-519. PubMed ID: 28707601
[TBL] [Abstract][Full Text] [Related]
11. Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma.
Zhang ZL; Liu ZS; Sun Q
World J Gastroenterol; 2006 Jul; 12(26):4241-5. PubMed ID: 16830384
[TBL] [Abstract][Full Text] [Related]
12. Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants.
Stratmann A; Acker T; Burger AM; Amann K; Risau W; Plate KH
Int J Cancer; 2001 Feb; 91(3):273-82. PubMed ID: 11169947
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors.
Yamakawa M; Liu LX; Date T; Belanger AJ; Vincent KA; Akita GY; Kuriyama T; Cheng SH; Gregory RJ; Jiang C
Circ Res; 2003 Oct; 93(7):664-73. PubMed ID: 12958144
[TBL] [Abstract][Full Text] [Related]
14. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
[TBL] [Abstract][Full Text] [Related]
16. Wogonin inhibits tumor angiogenesis via degradation of HIF-1α protein.
Song X; Yao J; Wang F; Zhou M; Zhou Y; Wang H; Wei L; Zhao L; Li Z; Lu N; Guo Q
Toxicol Appl Pharmacol; 2013 Sep; 271(2):144-55. PubMed ID: 23707765
[TBL] [Abstract][Full Text] [Related]
17. [Tumor angiogenesis: new approaches to cancer therapy].
Marmé D
Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
[TBL] [Abstract][Full Text] [Related]
18. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation.
Fujiyama S; Matsubara H; Nozawa Y; Maruyama K; Mori Y; Tsutsumi Y; Masaki H; Uchiyama Y; Koyama Y; Nose A; Iba O; Tateishi E; Ogata N; Jyo N; Higashiyama S; Iwasaka T
Circ Res; 2001 Jan; 88(1):22-9. PubMed ID: 11139469
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
